Willingness to pay for a QALY: past, present and future

References

• Johansson P-O. An Introduction to Modern Welfare Economics. Cambridge University Press, Cambridge, UK (1997).
   Google Scholar
• Smith R, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy74(1), 77–84 (2005).
   PubMed Web of Science ®Google Scholar
• Brouwer WBF, Van Exel J, Donaldson C, Baker R. The new myth: the social value of the QALY. Pharmacoeconomics26(1), 1–4 (2008).
   PubMed Web of Science ®Google Scholar
• Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain.27(1), 5–76 (2003).
   Web of Science ®Google Scholar
• Abelson P. The value of life and health for public policy. Econ. Rec.79, S2–S13 (2003).
   Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick M, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20, 332–342 (2000).
   PubMed Web of Science ®Google Scholar
• Johannesson M, Meltzer D. Some reflections on cost–effectiveness analysis. Health Econ.7(1), 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ. DOI: 10.1002/hec.1416 (2008) (Epub ahead of print).
   Google Scholar
• Persson U, Hjelmgren J. Halso – och sjukvarden behover kunskap om hur befolkingen varderar halsan. Lakartidningen43, 3436–3437 (2003).
   Google Scholar
• Fryback DG, Dasbach EJ, Klein R et al. The Beaver Dam Health Outcomes Study: initial catalogue of health-state quality factors. Med. Decis. Making13, 89–102 (1993).
   PubMed Web of Science ®Google Scholar
• King JT, Tsevat J, Lave J, Roberts MS. Willingness to pay for a quality adjusted life year: implications for societal health care resource allocation. Med. Decis. Making25(6), 667–677 (2005).
   PubMed Web of Science ®Google Scholar
• Blumenschein K, Johannesson M. Relationships between quality of life instruments, health states utilities and willingness to pay in patients with asthma. Ann. Allergy Asthma Immunol.80, 189–194 (1998).
   PubMedGoogle Scholar
• Cunningham SJ, Hunt NP. Relationship between utility values and willingness to pay in patients undergoing orthognathic treatment. Community Dent. Health17, 92–96 (2000).
   PubMedGoogle Scholar
• Zethraeus N. Willingness to pay for hormone replacement therapy. Health Econ.7, 31–38 (1998).
   PubMed Web of Science ®Google Scholar
• Olsen JA, Donaldson C. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc. Sci. Med.46(1), 1–12 (1998).
   PubMed Web of Science ®Google Scholar
• Ethgen O, Tancredi A, Lejeune E, Kvasz A, Zegels B. Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index. J. Rheumatol.30(11), 2452–2459 (2003).
   PubMed Web of Science ®Google Scholar
• Donaldson C, Baker R, Bateman I et al. Weighting and valuing quality adjusted life years: preliminary results from the Social Value of a QALY project. In: Report for the Methodology Programme. NIHR, Birmingham, UK (2008).
   Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ.12, 1049–1060 (2003).
   PubMed Web of Science ®Google Scholar
• Johannesson M, Johansson P-O. Quality of life and the WTP for an increase in life expectancy at an advanced age. J. Public Econ.65, 219–228 (1997).
   Web of Science ®Google Scholar
• Johnson FR, Desvousges WH, Ruby M, Stieb D, De Civita P. Eliciting stated health preferences: an application to willingness to pay for longevity. Med. Decis. Making18(Suppl.), S57–S67 (1998).
   Google Scholar
• Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality adjusted life year in a study of knee osteoarthritis. Med. Decis. Making25(6), 655–666 (2005).
   PubMed Web of Science ®Google Scholar
• Olsen JA. Aiding priority setting in health care: is there a role for the contingent valuation method? Health Econ.6, 603–612 (1997).
   PubMed Web of Science ®Google Scholar
• Van Houtven G, Powers J, Jessup A, Yang J-C. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ.15, 775–795 (2006).
   PubMed Web of Science ®Google Scholar
• Hammitt J, Liu J-T. Is there a ‘cancer premium’? Harvard Center for Risk Analysis12(2), (2004).
   Google Scholar
• Krupnick A, Alberini A, Cropper M et al. Age, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residents. J. Risk Uncertain.24(2), 161–186 (2002).
   Web of Science ®Google Scholar
• Alberini A, Cropper M, Krupnick A, Simon NB. Does the value of a statistical life vary with age and health status? Evidence from the US and Canada. J. Environ. Econ. Manage.48, 769–792 (2004).
   Web of Science ®Google Scholar
• O’Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. BMJ337:a1262 (2008).
   PubMedGoogle Scholar
• Kmietowicz Z. Professors call for review of way cancer drugs in NHS are rationed. BMJ337, a1450 (2008).
   Google Scholar
• House of Commons Health Committee. National Institute for Health and Clinical Excellence. House of Commons, The Stationary Office Limited, Norwich, UK (2007).
   Google Scholar
• Culyer A, McCabe C, Briggs A et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J. Health Serv. Res. Policy12, 56–58 (2007).
   PubMedGoogle Scholar
• Bate A, Murtagh M, Donaldson C. Managing to manage scarce resources in the English NHS. What can economics teach? What can economics learn? Health Policy84, 249–261 (2007).
   PubMed Web of Science ®Google Scholar